Literature DB >> 31141319

Treatment of Common Mental Disorders in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.

Mark Olfson1,2, Carlos Blanco3, Melanie M Wall2, Shang-Min Liu2, Bridget F Grant4.   

Abstract

OBJECTIVE: This study analyzed past 12-month disorder-specific mental health treatment patterns of common DSM-5 disorders in the United States.
METHODS: Nationally representative face-to-face household survey data from structured diagnostic interviews of the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III) (n = 36,309) were used to estimate percentages of respondents with 12-month DSM-5 mood, anxiety, and substance use disorders who received disorder-specific treatment during the 12 months before the interview.
RESULTS: The percentage receiving treatment was highest for mood disorders (37.8%; 95% CI, 36.1%-39.6%), followed by anxiety disorders (24.1%; 95% CI, 22.6%-25.6%), and lowest for substance use disorders (18.8%; 95% CI, 17.8%-19.8%). Among anxiety disorders, panic disorder (47.9%; 95% CI, 43.9%-52.0%) had the highest treatment rate, and among substance use disorders, tobacco use disorder (20.3%; 95% CI, 19.0%-21.7%) had the highest treatment rate. Adults with mood and anxiety disorders (53.1%; 95% CI, 49.7%-56.4%) were more likely than those with only mood (32.0%; 95% CI, 29.5%-34.6%) or only anxiety (13.2%; 95% CI, 11.6%-15.0%) disorders to receive any mental health treatment. Lack of insurance coverage was associated with significantly lower odds of treatment for all disorders except specific phobia (0.55; 95% CI, 0.30-1.03), drug use disorders other than tobacco (0.80; 95% CI, 0.47-1.36), and alcohol use disorder (1.52; 95% CI, 1.12-2.07).
CONCLUSIONS: Most adults with common mental disorders in the United States were not treated for their disorders, and treatment rates varied considerably across disorders and sociodemographic groups, with particularly low rates of treatment for substance use disorders. Policy and clinical interventions are needed to promote greater access to treatment of adults with common substance use, anxiety, and mood disorders. © Copyright 2019 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2019        PMID: 31141319     DOI: 10.4088/JCP.18m12532

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  Alcohol-involved overdose deaths in US veterans.

Authors:  Lewei A Lin; Erin E Bonar; Lan Zhang; Rachel Girard; Lara N Coughlin
Journal:  Drug Alcohol Depend       Date:  2021-11-26       Impact factor: 4.492

2.  The Amygdala and Depression: A Sober Reconsideration.

Authors:  Shannon E Grogans; Andrew S Fox; Alexander J Shackman
Journal:  Am J Psychiatry       Date:  2022-07       Impact factor: 19.242

3.  Healthcare coverage and service access for low-income adults with substance use disorders.

Authors:  Mark Olfson; Christine Mauro; Melanie M Wall; C Jean Choi; Colleen L Barry; Ramin Mojtabai
Journal:  J Subst Abuse Treat       Date:  2021-12-29

4.  Medicaid Expansion and Low-Income Adults with Substance Use Disorders.

Authors:  Mark Olfson; Melanie Wall; Colleen L Barry; Christine Mauro; Tianshu Feng; Ramin Mojtabai
Journal:  J Behav Health Serv Res       Date:  2020-11-06       Impact factor: 1.475

5.  The Kaiser Permanente Northern California Adult Alcohol Registry, an Electronic Health Records-Based Registry of Patients With Alcohol Problems: Development and Implementation.

Authors:  Vanessa A Palzes; Constance Weisner; Felicia W Chi; Andrea H Kline-Simon; Derek D Satre; Matthew E Hirschtritt; Murtuza Ghadiali; Stacy Sterling
Journal:  JMIR Med Inform       Date:  2020-07-22

6.  Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease.

Authors:  Heather Carney; Ruth Ann Marrie; James M Bolton; Scott B Patten; Lesley A Graff; Charles N Bernstein; Kaarina Kowalec
Journal:  Inflamm Bowel Dis       Date:  2021-01-01       Impact factor: 5.325

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.